Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLA1 | P09884 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146640 | 0.86 | MAPT (0.52) | MAPTPOLA1CDK1PDPK1GDA | |
| SCHEMBL16147176 | 0.86 | STAT3 (0.54) | MAPTPOLA1CDK1PDPK1GDA | |
| SCHEMBL16146760 | 0.86 | PRMT1 (0.56) | MAPTPOLA1CDK1PDPK1GDA | |
| SCHEMBL14939010 | 0.86 | CDK1 (0.65) | MAPTPOLA1CDK1PDPK1GDA | |
| SCHEMBL16145713 | 0.86 | MAPT (0.54) | MAPTCDK1PDPK1ADORA3STAT3 | |
| SCHEMBL16147160 | 0.86 | ALPL (0.50) | MAPTPOLA1CDK1PDPK1GDA | |
| SCHEMBL30523359 | 0.82 | POLA1 (0.46) | MAPTPOLA1CDK1PDPK1GDA | |
| SCHEMBL16147006 | 0.82 | POLA1 (0.46) | MAPTPOLA1CDK1PDPK1GDA | |
| SCHEMBL16145921 | 0.80 | CDK1 (0.76) | MAPTCDK1STAT3PDE4APDE4B | |
| SCHEMBL16147152 | 0.80 | ADORA2A (0.41) | MAPTCDK1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | MAPT 2548/4885POLA1 2876/4885CDK1 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.